{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T13:20:16Z","timestamp":1783171216691,"version":"3.54.6"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.radonc.2026.111592","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:21:09Z","timestamp":1778628069000},"page":"111592","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Response to the letter to the editor by Pontoriero et al. regarding the article \u201cCost-utility-analysis of molecular-integrated-profile for women with (high)intermediate risk endometrial cancer \u2013 PORTEC-4a an international randomised phase 3 trial by Van den Heerik et al.\u201d"],"prefix":"10.1016","volume":"220","author":[{"given":"Anne Sophie V.M.","family":"van den Heerik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanda","family":"Horeweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carien L.","family":"Creutzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert B.","family":"van den Hout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111592_b0005","article-title":"Quality-of-life assessment and long-term cost-effectiveness in PORTEC-4a: addressing the impact of recurrences","author":"Di Muzio","year":"2026","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111592_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2026.111406","article-title":"Cost-utility-analysis of molecular-integrated-profile for women with (high)intermediate risk endometrial cancer - PORTEC-4a an international, randomised, phase 3 trial","volume":"217","author":"van den Heerik","year":"2026","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111592_b0015","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ygyno.2007.08.072","article-title":"A cost-effective analysis of adjuvant therapies for the treatment of stage I endometrial adenocarcinoma","volume":"108","author":"Lachance","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.radonc.2026.111592_b0020","first-page":"829","article-title":"Health utilities in gynecological oncology and mastology in Germany","volume":"34","author":"Hildebrandt","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.radonc.2026.111592_b0025","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ygyno.2021.10.071","article-title":"Cost-effectiveness analysis of tumor molecular classification in high-risk early-stage endometrial cancer","volume":"164","author":"Orellana","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.radonc.2026.111592_b0030","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ygyno.2023.04.010","article-title":"Cost-effectiveness analysis of tumor molecular testing in stage III endometrial cancer","volume":"173","author":"Orellana","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.radonc.2026.111592_b0035","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.ygyno.2021.06.014","article-title":"Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: a cost-effectiveness analysis","volume":"162","author":"Barrington","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.radonc.2026.111592_b0040","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ygyno.2023.12.027","article-title":"Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy","volume":"182","author":"Dioun","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.radonc.2026.111592_b0045","doi-asserted-by":"crossref","first-page":"S445","DOI":"10.1016\/j.jval.2022.09.2216","article-title":"Health-related quality of life in patients with advanced or recurrent endometrial cancer who have disease progression on or following prior treatment with a platinum-containing therapy: analysis of EQ-5D utility scores (PCR283)","volume":"25","author":"Zhao","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.radonc.2026.111592_b0050","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1470-2045(25)00612-6","article-title":"Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial","volume":"27","author":"van den Heerik","year":"2026","journal-title":"Lancet Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026004317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026004317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T12:48:52Z","timestamp":1783169332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026004317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":10,"alternative-id":["S0167814026004317"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111592","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to the letter to the editor by Pontoriero et al. regarding the article \u201cCost-utility-analysis of molecular-integrated-profile for women with (high)intermediate risk endometrial cancer \u2013 PORTEC-4a an international randomised phase 3 trial by Van den Heerik et al.\u201d","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111592","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111592"}}